Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
09
2020
accepted:
07
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
12
1
2021
Statut:
epublish
Résumé
Various factors may determine the duration of viral shedding (the time from infection to viral RNA-negative conversion or recovery) in COVID-19 patients. Understanding the average duration of recovery and its predictors is crucial in formulating preventive measures and optimizing treatment options. Therefore, evidence showing the duration of recovery from COVID-19 in different contexts and settings is necessary for tailoring appropriate treatment and prevention measures. This study aimed to investigate the average duration and the predictors of recovery from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection among COVID-19 patients. A hospital-based prospective cohort study was conducted at Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center from March 18 to June 27, 2020. The Center was the first hospital designated to manage COVID-19 cases in Ethiopia. The study participants were all COVID-19 adult patients who were admitted to the center during the study period. Follow up was done for the participants from the first date of diagnosis to the date of recovery (negative Real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCT) test of throat swab). A total of 306 COVID-19 cases were followed up to observe the duration of viral clearance by rRT-PCR. Participants' mean age was 34 years (18-84 years) and 69% were male. The median duration of viral clearance from each participant's body was 19 days, but the range was wide: 2 to 71 days. Cough followed by headache was the leading sign of illness among the 67 symptomatic COVID-19 patients; and nearly half of those with comorbidities were known cancer and HIV/AIDS patients on clinical follow up. The median duration of recovery from COVID-19 was different for those with and without previous medical conditions or comorbidities. The rate of recovery from SARS-CoV-2 infection was 36% higher in males than in females (p = 0.043, CI: 1.01, 1.85). The rate of recovery was 93% higher in those with at least one comorbidity than in those without any comorbidity. The risk of delayed recovery was not influenced by blood type, BMI and presence of signs or symptoms. The findings showed that study participants without comorbidities recovered more quickly than those with at least one comorbidity. Therefore, isolation and treatment centers should be prepared to manage the delayed stay of patients having comorbidity.
Sections du résumé
BACKGROUND
Various factors may determine the duration of viral shedding (the time from infection to viral RNA-negative conversion or recovery) in COVID-19 patients. Understanding the average duration of recovery and its predictors is crucial in formulating preventive measures and optimizing treatment options. Therefore, evidence showing the duration of recovery from COVID-19 in different contexts and settings is necessary for tailoring appropriate treatment and prevention measures. This study aimed to investigate the average duration and the predictors of recovery from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection among COVID-19 patients.
METHOD
A hospital-based prospective cohort study was conducted at Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center from March 18 to June 27, 2020. The Center was the first hospital designated to manage COVID-19 cases in Ethiopia. The study participants were all COVID-19 adult patients who were admitted to the center during the study period. Follow up was done for the participants from the first date of diagnosis to the date of recovery (negative Real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCT) test of throat swab).
RESULT
A total of 306 COVID-19 cases were followed up to observe the duration of viral clearance by rRT-PCR. Participants' mean age was 34 years (18-84 years) and 69% were male. The median duration of viral clearance from each participant's body was 19 days, but the range was wide: 2 to 71 days. Cough followed by headache was the leading sign of illness among the 67 symptomatic COVID-19 patients; and nearly half of those with comorbidities were known cancer and HIV/AIDS patients on clinical follow up. The median duration of recovery from COVID-19 was different for those with and without previous medical conditions or comorbidities. The rate of recovery from SARS-CoV-2 infection was 36% higher in males than in females (p = 0.043, CI: 1.01, 1.85). The rate of recovery was 93% higher in those with at least one comorbidity than in those without any comorbidity. The risk of delayed recovery was not influenced by blood type, BMI and presence of signs or symptoms. The findings showed that study participants without comorbidities recovered more quickly than those with at least one comorbidity. Therefore, isolation and treatment centers should be prepared to manage the delayed stay of patients having comorbidity.
Identifiants
pubmed: 33378367
doi: 10.1371/journal.pone.0244269
pii: PONE-D-20-28633
pmc: PMC7773180
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244269Déclaration de conflit d'intérêts
NO authors have competing interests.
Références
Aging Cell. 2015 Jun;14(3):309-21
pubmed: 25720438
Br J Haematol. 2020 Jul;190(1):24-27
pubmed: 32379894
Transfus Apher Sci. 2020 Oct;59(5):102838
pubmed: 32513613
Chest. 2020 Nov;158(5):1876-1884
pubmed: 32569635
Nat Commun. 2020 Nov 13;11(1):5761
pubmed: 33188185
Vaccine. 2000 Feb 25;18(16):1686-9
pubmed: 10689149
Int J Infect Dis. 2020 Jul;96:531-537
pubmed: 32425636
Sci Total Environ. 2020 Aug 1;728:138812
pubmed: 32335406
Transfusion. 2020 Aug;60(8):1883-1884
pubmed: 32562280
Int J Infect Dis. 2020 Sep;98:252-260
pubmed: 32619760
Spec Care Dentist. 2020 Sep;40(5):470-474
pubmed: 32706510
J Infect. 2020 Aug;81(2):e102-e103
pubmed: 32425274
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1149-1151
pubmed: 32668401
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398298
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2021 Jan;93(1):506-512
pubmed: 32644223
medRxiv. 2020 Aug 14;:
pubmed: 32817977
Obes Res Clin Pract. 2020 May - Jun;14(3):205-209
pubmed: 32534848
Ann Hematol. 2020 Sep;99(9):2113-2118
pubmed: 32656591
Infect Genet Evol. 2020 Oct;84:104485
pubmed: 32739464
J Intern Med. 2020 Jul;288(1):128-138
pubmed: 32220033
Hum Reprod Update. 2005 Jul-Aug;11(4):411-23
pubmed: 15817524
Exp Gerontol. 2007 May;42(5):400-6
pubmed: 17218073
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
J Med Virol. 2021 Feb;93(2):952-961
pubmed: 32725915
ACS Nano. 2020 Apr 28;14(4):3822-3835
pubmed: 32223179
J Infect Dis. 2020 Aug 17;222(6):910-918
pubmed: 32614392